Clinical Trial News and Research

RSS

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).

11 Feb 2014

Short-Form OAB questionnaire validated

Researchers from the USA have developed a short form version of the overactive bladder questionnaire, which they say can capture the full spectrum of symptom bother and quality of life impact, while being more convenient than the full version of the test.

10 Feb 2014

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.

10 Feb 2014

KKH doctors develop novel DIVA System for blood pressure management

New trial results1 have shown that the world's first Double Intravenous Vasopressor Automated (DIVA) System affords superior control of maternal blood pressure in women undergoing caesarean section under spinal anaesthesia, when compared with manually-administered medication to manage reduced blood pressure (vasopressor).

10 Feb 2014

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).

10 Feb 2014

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.

10 Feb 2014

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.

10 Feb 2014

PHT‘s LogPad App System receives Clinical Informatics News Best Practices Award

The PHT Corporation LogPad App System was a finalist for the Clinical Informatics News Best Practices Awards announced February 6 at the SCOPE Summit for Clinical Ops Executives.

10 Feb 2014

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

Study identifies seven new genetic regions associated with type 2 diabetes

Seven new genetic regions associated with type 2 diabetes have been identified in the largest study to date of the genetic basis of the disease.

9 Feb 2014

Glimmer of hope for Alzheimer’s disease sufferers

Hope may be on its way for sufferers of Alzheimer’s Disease as the Griffith Health Institute seeks participants for new research.

7 Feb 2014

Proprietary supplement improves cognitive processing speed of older adults

Declines in the underlying brain skills needed to think, remember and learn are normal in aging. In fact, this cognitive decline is a fact of life for most older Americans.

7 Feb 2014

Talking therapy may provide effective alternative to medication for people with schizophrenia

Cognitive therapy may provide an effective alternative to antipsychotic medication for patients with schizophrenia, report researchers.

6 Feb 2014

UTHealth unveils country's first Mobile Stroke Unit

The University of Texas Health Science Center at Houston (UTHealth) Medical School, in partnership with Memorial Hermann-Texas Medical Center, has unveiled the country's first Mobile Stroke Unit.

6 Feb 2014

Chemotherapy following radiation therapy improves survival for adults with brain tumor

Adults with low-grade gliomas, a form of brain tumor, who received a chemotherapy regimen following completion of radiation therapy, lived longer than patients who received radiation therapy alone, according to long-term follow-up results from a National Institutes of Health-supported randomized controlled clinical trial.

6 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Clinical Trial News and Research

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Omeros announces additional positive data from OMS824 Phase 1 program

Short-Form OAB questionnaire validated

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

KKH doctors develop novel DIVA System for blood pressure management

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Mallinckrodt announces commercial launch of PENNSAID

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

PHT‘s LogPad App System receives Clinical Informatics News Best Practices Award

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

pSivida announces financial results for second quarter 2014

Study identifies seven new genetic regions associated with type 2 diabetes

Glimmer of hope for Alzheimer’s disease sufferers

Proprietary supplement improves cognitive processing speed of older adults

Talking therapy may provide effective alternative to medication for people with schizophrenia

UTHealth unveils country's first Mobile Stroke Unit

Chemotherapy following radiation therapy improves survival for adults with brain tumor

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer